WC
VYGR icon

Wexford Capital’s Voyager Therapeutics VYGR Stock Holding History

Wexford Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,007
Closed -$42.1K – 539
2025
Q3 		$42.1K Buy
+9,007
New +$32.6K 0.01% 318

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wexford Capital's VYGR Position: Q4 2025 in Review

Wexford Capital sold out of Voyager Therapeutics (VYGR) in Q4 2025, closing a stake of 9,007 shares — an estimated $42.1K sold.

Wexford Capital first reported a position in VYGR in Q3 2025 and held it in 1 quarter. The position peaked at $42.1K in Q3 2025. 125 funds tracked by Wall St. Rank hold VYGR as of Q4 2025.

  • Wexford Capital reported no remaining Voyager Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 9,007 Voyager Therapeutics shares in Q4 2025, an estimated $42.1K.
  • Wexford Capital first reported a position in Voyager Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wexford Capital's Voyager Therapeutics position peaked at $42.1K in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.